Business Wire

25,000 Health Facilities Across India Are Transforming Public Health Systems to Address Growing Critical Climate Issues

7.4.2023 12:00:00 EEST | Business Wire | Press release

Share

In 2021, WHO identified climate change as the biggest global health threat of the 21st century. While half of the world’s population continue to lack access to essential health services, according to a 2019 Health care climate footprint report, if the healthcare sector were a country, it would be the fifth largest greenhouse gas emitter on the planet.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230407005011/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Aerial view of Khudei Khunou Health facility in North East India (Photo: Business Wire)

In a significant step towards transforming the public health infrastructure for improved sustainability, SELCO Foundation and IKEA Foundation, in partnership with India’s Ministry of Health and Family Welfare (MOHFW) and various State Health Missions, have launched a groundbreaking initiative ‘Energy for Health’. The program recognises climate adaptation and mitigation at the center to all efforts to upgrade the public health facilities across the world.

Speaking about the significance of this program globally, Dr. Maria Neira, Assistant Director-General a.i., Division of Healthier Populations, and Director, Department of Environment, Climate Change and Health, at the World Health Organization said, “Reliable electricity in health-care facilities is essential to save lives and to provide quality health care. And yet, one billion people around the world are still served by health-care facilities without reliable electricity or with no electricity access at all. Decentralized renewable energies represent a key opportunity to accelerate electrification of health-care facilities, including in remote areas. I congratulate the Government of India and our partners from Selco Foundation and Ikea Foundation for this critical program, which will have a transformative impact on strengthening the health system”.

The first-of-a-kind initiative will bring solar energy solutions with efficient medical and electrical equipment to 25,000 healthcare facilities in 12 states by 2026. Across the 12 states under this program, there is a diversity in terms of topography, socio-economic vulnerabilities, disease burden and climate. This diversity across selected geographies will contribute to this programme serving as a showcase globally- innovating on approaches, models and processes relevant for similar contexts in other parts of the world.

Reflecting on India’s leadership in the effort, Dr. Harish Hande, CEO of SELCO Foundation said, “Affordable and equitable access to healthcare is a function of two aspects- one, resources required to deliver health care, and two, cost of accessing health care. Through this program, SELCO Foundation and IKEA Foundation, along with India’s Ministry of Health and Family Welfare (MOHFW) and various State Health Missions, will showcase at scale how sustainable energy can be used to make health services affordable at the doorstep of the poor.”

‘Energy for Health’ initiative brings with it positive impacts across the spectrum of stakeholders- for last mile communities in their access to timely healthcare; for health facility staff in ensuring a conducive work environment to provide quality services; for health sector in reducing energy and equipment-related costs as well as avoiding wastage of vaccines and other critical resources; reinforcing climate resilience building and carbon mitigation efforts while ensuring positive health outcomes for all citizens.

Mr. Per Heggenes, CEO of IKEA Foundation said, “‘At the IKEA Foundation, we strongly believe caring for the health of people and our planet must go hand-in-hand. This initiative will improve healthcare outcomes and reduce emissions, by providing reliable and renewable energy to thousands of clinics. Our hope is that the success of this programme can serve as a model for building effective and efficient health systems globally.’

Supported by IKEA Foundation, through this initiative, SELCO Foundation along with Government of India will create systems and processes that demonstrate ownership, management, and regular maintenance of the energy systems and appliances. Together, through the 25,000 public health facilities, technical knowledge and capacity, as well as guidelines and policies that enable health staff at different levels to plan for public health infrastructure in a sustainable manner will be improved. The program will also improve the local technical network for solar energy, which could potentially also have indirect impacts on local economies and boost adoption of solar energy across other sectors as well.

The initiative aims to reach over 170 million people across the 12 states and improve working conditions for over 160,000 front line health staff at these health facilities. Across the 25,000 public health facilities, this will add ~100MW of solar energy capacity in the country, and mitigate over 3 million tonnes of CO2e emissions over a 20 year period. These will directly contribute to India’s Net Zero targets, while also creating a paradigm shift on how health targets can be achieved for resource constrained communities across the world in an efficient manner.

About the partners:

SELCO Foundation:
Established in 2010, SELCO Foundation’s mission is to develop holistic solutions that use sustainable energy as a catalyst to address poverty alleviation alongside ensuring environmental sustainability. SELCO's interventions lead to the sustainable delivery of essential services such as healthcare, and enable improvements in livelihoods productivity and till date more than 7 million people have been impacted. The foundation does this by also developing enabling conditions, i.e the ecosystem for sustainable energy solutions to be locally developed, adopted, scaled and institutionalized through stakeholders including government agencies, financiers, local NGOs and enterprises.

For more information, visit www.selco foundation.org, and follow them on Twitter (@SELCOFoundation) and LinkedIn.

IKEA Foundation:
The IKEA Foundation is a strategic philanthropy that focuses its grant making efforts on tackling the two biggest threats to children’s futures: poverty and climate change. It currently grants more than €200 million per year to help improve family incomes and quality of life while protecting the planet from climate change. Since 2009, the IKEA Foundation has granted more than €1.5 billion to create a better future for children and their families.

In 2021 the Board of the IKEA Foundation decided to make an additional €1 billion available over the next five years to accelerate the reduction of Greenhouse Gas emissions.

Learn more at: www.ikeafoundation.org or by following them on LinkedIn or Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lotika Mehta
lotika.mehta@ikeafoundation.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye